VIATRIS INC. for VIATRIS INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Part D Formulary Design and Generic Drug Tiering Electronic Labeling of Prescription Drugs FDA facility inspections Medicare incentives for biosimilar utilization Generic Drug User Fee Amendments (GDUFA) Complex Generic Drug Approvals H.R. 3 - Lower Drug Costs Now Act H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act Biosimilar interchangeability H.R. 5376 - Build Back Better Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Trade (domestic/foreign) TRD
Trade issues related to generic medicines Pharmaceutical supply chain
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
Taxation/Internal Revenue Code TAX
Corporate Tax Policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
| PETER WALLACE | — |
Budget/Appropriations BUD
Medicaid Rebate provision of the Bipartisan Budget Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Financial Institutions/Investments/Securities FIN
Policy related to corporate governance
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
Copyright/Patent/Trademark CPT
Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs Patent Settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.